Eleonora Teplinsky, MD | Authors

Endocrine Therapy for Premenopausal Hormone-Responsive Breast Cancer: What Is the Optimal Therapy?

June 09, 2014

The breast cancer treatment landscape is changing, and the optimal adjuvant endocrine therapy for premenopausal women with hormone receptor (HR)-positive breast cancer is uncertain.

The Presidential Address: Setting Intentions

June 03, 2014

In his address, Dr. Clifford Hudis proposed the following solutions for achieving social justice in cancer care: creating more private and public resources, addressing disparities in cancer risk and in access to high-quality care, defining “value” in cancer care, and harnessing the new power of information technology.

HE4: Another ‘Player’ in the Epithelial Tumor Marker Arena?

June 15, 2013

While a prominent role for HE4 in these areas remains to be determined, this thorough review of HE4 demonstrates that the biomarker is complementary to, and occasionally more useful than, the widely used CA 125 in the management of gynecologic malignancies.